Additionally, a successor vaccine—CV9202—was investigated in combination with local radiation therapy in patients with stage IV NSCLC (NCT01915524), encoding six NSCLC-associated antigens: Mucin1 (MUC1), survivin, NY-ESO-1, 5T4, MAGE-C2, and MAGE-C1. This evidence concerns the gene BIRC5 and non-small cell lung carcinoma.